Icon PlcICLR
Price (close)
$173.90
Market cap
$13.4B
P/E
58.5x
Revenue (FY)
$8.3B
Net income
$229.3M
Dividend yield
—
1-year total return
7.0%
Net margin
2.8%
Revenue growth
0.8%
Debt / equity
0.31x
What Icon Plc does.
ICON is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations.
We offer a full range of clinical, consulting and commercial services that range from clinical development strategy, planning and trial design, to full study execution, and post-market commercialization.
ICON provides its services across a range of clinical outsourcing operating models including strategic partnerships, preferred provider, full-service delivery to functional service provision and stand-alone services.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.8B | $5.5B | $7.7B | $8.1B | $8.2B | $8.3B |
| Net income | $332.3M | $153.2M | $505.3M | $554.2M | $739.1M | $229.3M |
| Free cash flow | $527.1M | $735.4M | $421.2M | $1.0B | $1.1B | $862.0M |
More on ICLR.
- Icon Plc summary
- Icon Plc financial statements
- Icon Plc key metrics
- Icon Plc health scores and style box
- Icon Plc earnings
- Icon Plc dividends
- Icon Plc valuation
- Icon Plc ownership and insiders
- Icon Plc peers
Figures from Icon Plc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.